Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1643 1644 1646 1647 1653 1654
This examiner grants 64% of resolved cases
Michail A. Belyavskyi is an examiner in Tech Center 1600, specifically within Art Unit 1641, with 1115 resolved cases. The examiner maintains an allowance rate of 64.2 percent, which provides a baseline for applicants. This 64.2 percent figure indicates the probability of securing a patent grant on this docket. Understanding this rate is essential for setting expectations during the prosecution phase. The 1115 resolved cases provide a robust statistical foundation.
The interview lift is 27.6 percent, which is a positive indicator for the effectiveness of oral advocacy. This 27.6 percent lift suggests that an interview can improve the chances of allowance compared to the 64.2 percent baseline. Practitioners should view the interview as a strategy for overcoming rejections on this docket. The median days to allowance is 1149, representing the typical duration for applications that reach a grant. This 1149 median days to allowance helps define the expected timeline for prosecution.
The data in Art Unit 1641 shows that the interview lift is 27.6 percent, offering a clear roadmap for success. The 1149 median days to allowance helps set expectations for the overall timeline in Tech Center 1600. The 64.2 percent allowance rate remains a key metric for evaluating the likelihood of a grant. These metrics emphasize the importance of proactive engagement with the examiner to achieve a positive outcome.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18671662 | Primary T-Cell Expansion | Non-Final OA | NantBio, Inc. |
| 18651221 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | Non-Final OA | Genentech, Inc. |
| 18636947 | CELL-BASED ASSAY FOR DETECTING ANTl-CD3 HOMODIMERS | Non-Final OA | Genentech, Inc. |
| 17863149 | METHODS FOR TREATING VIRAL INFECTIONS | Non-Final OA | The Regents of The University of California |
| 18691410 | METHODS OF AMPLIFYING TUMOR-REACTIVE IMMUNE POPULATIONS USING ORGANOIDS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17793024 | PERICYTE-SPARING THERAPY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17923029 | METHODS FOR TREATING OR REDUCING THE SEVERITY OF A VIRAL INFECTION | Non-Final OA | Washington University |
| 18044482 | ENGINEERED IMMUNE CELLS FOR REAGENT DELIVERY | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18041542 | CHIMERIC ANTIGEN RECEPTOR T CELLS FOR TREATING AUTOIMMUNITY | Final Rejection | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 17874767 | METHODS AND COMPOSITIONS OF NATURAL KILLER CELL ADOPTIVE TRANSFER THERAPY | Non-Final OA | RESTEM LLC |
| 17996828 | METHODS FOR TREATING BLADDER CANCER | Final Rejection | Board of Regents, The University of Texas System |
| 17800387 | CAR T CELLS TARGETING THE INTEGRIN ALPHAV BETA3 EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST GLIOMAS AND OTHER SOLID TUMOR MALIGNANCIES | Final Rejection | University of Virginia Patent Foundation |
| 18656496 | METHOD FOR PRODUCING CD8alpha+beta+ CYTOTOXIC T CELLS | Non-Final OA | KYOTO UNIVERSITY |
| 18279557 | CELL FUSION METHOD | Non-Final OA | OSAKA UNIVERSITY |
| 18539876 | METHOD FOR PRODUCING NATURAL KILLER CELLS FROM PLURIPOTENT STEM CELLS | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18098792 | ANTIGEN BINDING PROTEINS | Final Rejection | GlaxoSmithKline Intellectual Property Development Limited |
| 18277367 | TRUNCATED DOMAIN IV EGFR AND USES THEREOF | Non-Final OA | CITY OF HOPE |
| 18020858 | COMPOSITIONS AND USES OF SARS-COV-2 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED NK CELLS | Non-Final OA | City of Hope |
| 18682778 | INDUCIBLE SYSTEMS FOR ALTERING GENE EXPRESSION IN HYPOIMMUNOGENIC CELLS | Non-Final OA | Sana Biotechnology, Inc. |
| 18290132 | ANTIGEN BINDING MOLECULE SPECIFICALLY BINDING TO RANKL AND NGF, AND MEDICAL USE THEREOF | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18603451 | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY | Non-Final OA | FIGENE, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy